Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IC43 Vaccine in ICU Patients
NCT01563263Phase 3Completed
- Sponsor
- Valneva
- Start
- Mar 2012
- Primary completion
- Aug 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
A Phase 3 trial of IC43 in Pseudomonas aeruginosa infection, sponsored by Valneva. Started Mar 2012; status: completed.
02
Drugs
IC43
03
Conditions
Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT01563263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01563263.